Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.